Jacobs Levy Equity Management, Inc Amylyx Pharmaceuticals, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q1 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 77,091 shares of AMLX stock, worth $373,120. This represents 0.0% of its overall portfolio holdings.
Number of Shares
77,091
Previous 314,939
75.52%
Holding current value
$373,120
Previous $1.19 Million
77.09%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding AMLX
# of Institutions
150Shares Held
73MCall Options Held
148KPut Options Held
98.7K-
Perceptive Advisors LLC New York, NY7.87MShares$38.1 Million1.17% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.94MShares$28.8 Million5.07% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.7MShares$27.6 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.12MShares$19.9 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.08MShares$14.9 Million0.01% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $283M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...